Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

Next Previous
Search
Trial Profile

Open-Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 09 Nov 2023 Results of pooled post hoc analysis POLYP 1 and POLYP 2 and the open-label extension (OLE) trials assessing impact of the allergic and asthma status on omalizumab treatment in patients with CRSwNP published in the Annals of Allergy, Asthma and Immunology
    • 01 Mar 2021 Results of an exploratory analysis assessing the impact of Omalizumab therapy on sleep in patients With Nasal Polyps presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 19 Mar 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top